In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Results: The study included 62 patients (43.5% female, mean age 68 ± 8.9 years). Of these, 46 were on Apixaban, 12 on Dabigatran, and 5 on Rivaroxaban. Recurrent thromboembolic events occurred in 13 ...

9 In this context, we aimed to better estimate the risk of hepatic adverse drug reactions associated with NOAC by performing a systematic review and meta-analysis of phase III randomised controlled ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Patients receiving treatment with direct oral anticoagulants (DOACs) are at high risk for ischemic stroke and delayed ... The cohort comprised 9729 patients — 1087 in the dabigatran group, 3046 in the ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...